Taysha Gene Therapies (TSHA) Proxy Filing summary

Executive summary

• Annual Meeting scheduled for June 2, 2025, to be held virtually, with record date of April 3, 2025.

• Stockholders will vote on director elections, auditor ratification, and an amendment to increase authorized common stock.

• Proxy materials are primarily distributed online, with options for voting by internet, phone, or mail.

Voting matters and shareholder proposals

• Election of two Class II directors to serve until 2028.

• Ratification of Deloitte & Touche LLP as independent auditor for 2025.

• Approval to increase authorized common stock from 400,000,000 to 700,000,000 shares.

• Procedures for submitting shareholder proposals and director nominations for 2026 are detailed, with deadlines and requirements.

Board of directors and corporate governance

• Board consists of six members, with a mix of industry, financial, and scientific expertise.

• Four directors are independent per Nasdaq standards; CEO serves as Board Chair.

• Board has Audit, Compensation, Nominating and Corporate Governance, and Clinical and Scientific Committees.

• Board met five times in the last fiscal year; all directors attended at least 75% of meetings.

• Board diversity includes gender and ethnic representation.